Clinicians from the McGill University Health Centre and the Centre hospitalier de l'Université de Montréal (CHUM) are participating in the first Canadian therapeutic HIV vaccine trial. Funded by a number of public and private institutions,
Early results from a major, international Phase III clinical trial decisively show that recurrent multiple myeloma is more effectively treated with the drug bortezomib (trade name: Velcade TM) than with dexamethasone, a drug that for decades has been the s
A new multi-targeted anticancer drug called SU11248 has shown very promising results in the treatment for metastatic renal cell cancer, one of the most chemotherapy resistant of all cancers. The study's lead investigator, Robert Motzer, MD, attending physi
Breast cancer patients with advanced disease live longer when treated with a new drug, gemcitabine, in combination with paclitaxel, a traditional drug, according to results of a landmark global phase III study presented today at the American Society of Cli
New research presented by Peter Weissman, M.D., from the University of Miami, at the 64th Annual Scientific Sessions of the American Diabetes Association shows that combination treatment with rosiglitazone maleate and metformin significantly improves ce
Patients with Type 2 diabetes and a CV risk factor would benefit from a cholesterol-lowering medicine according to results from the first ever specifically designed UK primary prevention statin trial announced today at the American Diabetes Association
Attendees at the 40th annual meeting of the Association of Clinical Oncologists were updated on the serum estrogen receptor modulator (SERM) raloxifene and the aromatase inhibitor (AI) exemestane. Newest research findings were presented on the possible
Research presented today showed that the investigational drug, LAF237, the first in a new class, improved glycemic control in patients with type 2 diabetes. In this study, LAF237, which is administered as a tablet to be taken orally, was added to the st
Early testing of an experimental human monoclonal antibody showed a striking benefit in patients with advanced melanoma, say researchers at The University of Texas M. D. Anderson Cancer Ce
According to a study conducted at The University of Texas M. D. Anderson Cancer Center, more than twice as many women with early stage, HER-2 positive breast disease who received Herceptin
Dr Jon Whitehead, from the Centre for Diabetes and Endocrine Research, has identified an enzyme that appears to play a critical role in fat accumulation in cells - an occurrence in which specialised fat cells can expand their lipid stores up to 1000 times.
The enzyme may also be involved in proliferation of these fat cells.
By inhibiting the enzyme in fat cell precursors, Dr Whitehead hopes to halt adipogenesis - the process of fat cell multiplication and lipid accumulation - and ultimately to treat obesity.
"This is an extremely important development in our understanding of adipogenesis and, ultimately, may allow us to develop a novel obesity drug," Dr Whitehead said.
His research has moved closer to a marketplace reality following his recent win in Trailblazer 2004, an innovation competition run by UniQuest, UQ's main commercialisation company.
UniQuest Managing Director, David Henderson said the company had a provisional patent and was working to secure an investment to progress the research.
"UniQuest was very impressed with Dr Whitehead's obesity research and we believe it has significant commercial potential," Mr Henderson said.
"With more than a billion people globally affected by obesity and at increased risk of suffering from health complications such as type two diabetes, there is a clear need for effective medical treatments."
Until entering the Trailblazer competition Dr Whitehead said he had not given serious consideration to the likelihood that his research could contribute directly to the social and economic benefit of society.
"There was little commercial structure to my thinking because it's the science that fascinates me, hence I wasn't focusing on the commercial implications.
"UniQuest prompted me to consider my research in a new way, to look further a field."
http://www.uq.edu.au